American Bio Medica (American Bio Medica) Cash-to-Debt : 0.39 (As of Mar. 2023)

View and export this data going back to . Start your Free Trial

What is American Bio Medica Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. American Bio Medica's cash to debt ratio for the quarter that ended in Mar. 2023 was 0.39.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, American Bio Medica couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2023.

The historical rank and industry rank for American Bio Medica's Cash-to-Debt or its related term are showing as below:

ABMC's Cash-to-Debt is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.35
* Ranked among companies with meaningful Cash-to-Debt only.

American Bio Medica Cash-to-Debt Historical Data

The historical data trend for American Bio Medica's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

American Bio Medica Cash-to-Debt Chart

American Bio Medica Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

0.07

0.05

0.07

0.02

American Bio Medica Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash-to-Debt	Get a 7-Day Free Trial															0.01	-	0.01	0.02	0.39

Competitive Comparison of American Bio Medica's Cash-to-Debt

For the Diagnostics & Research subindustry, American Bio Medica's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

American Bio Medica's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Bio Medica's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where American Bio Medica's Cash-to-Debt falls into.

American Bio Medica Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

American Bio Medica's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.034	/	(2.234	+	0.006)
	=	0.02

American Bio Medica's Cash to Debt Ratio for the quarter that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.068	/	(0.175	+	0)
	=	0.39

American Bio Medica (OTCPK:ABMC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

American Bio Medica Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of American Bio Medica's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

American Bio Medica (American Bio Medica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Bio Medica Corp (OTCPK:ABMC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

122 Smith Road, Kinderhook, New York, NY, USA, 12106

Website

https://www.abmc.com

American Bio Medica Corp is a us-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.

Executives

Stuart Steinberg	10 percent owner	85 BELLEVUE AVENUE, RYE NY 10580
John J Moroney	10 percent owner	118 PEGASUS DR., JUPITER FL 33477
Chaim Davis	director	2601 PINE TREE DRIVE, MIAMI BEACH FL 33140
Peter Jerome	director	7 RIDGECREST AVE, LATHAM NY 12110
Diane Generous	director	122 SMITH ROAD, KINDERHOOK NY 12106
Melissa A Waterhouse	officer: EVP, CCO, CORP SEC	AMERICAN BIO MEDICA CORPORATION, 122 SMITH ROAD, KINDERHOOK NY 12106
Mp Biomedicals Llc	10 percent owner	3 HUTTON CENTRE DRIVE, SUITE 100, SANTA ANA CA 92707
Douglas Casterlin	officer: Executive Vice President	C/O MELISSA A. WATERHOUSE/ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Jean Neff	director	C/O ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Stefan Parker	officer: Chief Financial Officer	122 SMITH ROAD, KINDERHOOK NY 12106
Carl A Florio	director	C/O HUDSON RIVER BANK & TRUST CO, PO BOX 76, HUDSON NY 12534
Stan Cipkowski	director	300 S LAKE DR, STE 340, FISHKILL NY 12553
Anthony G Costantino	director	122 SMITH ROAD, KINDERHOOK NY 12106
Edmund M Jaskiewicz	director, officer: President
Richard Koskey	director	C/O ABMC 122 SMITH ROAD, 122 SMITH ROAD, KINDERHOOK NY 12106